IL13 and Alzheimer disease: Finally, circulating cytokines IL-4 and IL-13, which are the therapeutic targets of dupilumab, were not measured, as such testing is not routinely performed in AD care across Italian centers; therefore, pathophysiologic correlations between cytokine levels and clinical outcomes could not be explored.